One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...

Lilly's retatrutide shows remarkable weight loss in trials but raises concerns with side effects possibly linked to the drug like nausea and kidney stones. Read more here.

Aristotle Atlantic’s Focus Growth Composite posted a total return of 5.05% gross of fees, underperforming the 7.07% total return of the Russell 1000 Growth Index.

The use of semaglutide (Ozempic) was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in ...

Gut health is about how well your body digests food, absorbs nutrients, and maintains a balance of good and bad bacteria.

For individuals with type 1 diabetes, intraindividual body weight variability, or body weight cycling, is associated with an increased risk for renal events.

American doctors, who tracked over 37 million people, said the injections put users at higher risk of nonarteritic ischemic ...

Patients with type 1 diabetes comorbid with metabolic dysfunction-associated steatotic liver disease had a low prevalence of advanced liver fibrosis.

Many patients with overweight or obesity discontinue glucagon-like peptide-1 receptor agonist therapy within one year.